schizophrenia and other severe mental health conditions. Competing drugs include Risperdal
and Zyprexa. Bristol Myers and Omnicare conspired to switch many atypical antipsychotic
prescriptions for Omnicare-serviced patients from Risperdal and other atypical antipsychotics to
implementation of the Abilify scheme included but were not limited to, Robert W. McBrier,
Thomas Libassi, Matthew Kryczko, Jackly Bryon, John E. Hanson, Maryann Giorgianni, Leslie
T. Hirsch, Director of Managed Care Operations, Frances E. Hamer, John V. Mollica, and
Sandra E. Pittman.
Bristol Myers' representatives often visited Omnicare locations for the purpose of
promoting the switches. Bristol Myers developed special materials targeted solely to Omnicare
pharmacists and physicians in Omnicare-serviced nursing homes to "educate" these audiences on
the importance of the switching program and on how to switch patients from Risperdal and other
atypical antipsychotics to Abilify - including, potentially - many patients who had previously
been switched from atypical antipsychotics to Risperdal previously.
met with Omnicare
commencement of mass switching to Abilify to educate pharmacists on how to make the
switches. Meetings were held with Omnicare front line staff where Bristol Myers' marketing
staff informed Omnicare's front line pharmacists and phannacy supervisors that the switches
were not only going to be beneficial to patients in Omnicare-serviced long-term care facilities,
but would save payors money.
Bristol Myers also made marketing agents available to Omnicare pharmacists who
needed subsequent technical assistance to switch patients from Risperdal and other atypical